Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment

• Status: Completed
• Trial end date: 2015-10-01

Summary

The purpose of this study is to evaluate the efficacy and safety of febuxostat 40 mg extended release (XR) and 80 mg XR in comparison with febuxostat 40 mg immediate release (IR) and 80 mg IR, respectively, in gout participants with moderate renal impairment.

• Phase: Phase 2

Details

• Lead Sponsor: Takeda
• Treatments: Colchicine; Dexlansoprazole; Febuxostat; Lansoprazole; Naproxen